Checkmate 77T: Perioperative chemoimmunotherapy outperforms in early-stage NSCLC

被引：0

作者：

Brazel, Danielle ^{[1
]}

Nagasaka, Misako ^{[2
,3
]}

机构：

[1] Scripps Green Hosp, Scripps Clin, Dept Hematol Oncol, 10166 N Torrey Pines Rd, La Jolla, CA 92037 USA

[2] Univ Calif Orange, Chao Family Canc Ctr, Irvine Sch Med, 101 City Dr, Orange, CA 92868 USA

[3] St Marianna Univ, Sch Med, Kawasaki, Japan

来源：

MED | 2024年 / 5卷 / 08期

关键词：

D O I：

10.1016/j.medj.2024.06.012

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Approximately 1 in 4 patients with NSCLC present with resectable disease. Although surgery is potentially curative, 30%-50% of patients relapse. Studies have shown that neoadjuvant, adjuvant, and perioperative chemoimmunotherapy improve outcomes. The Checkmate 77T trial explored if perioperative platinum-based chemotherapy plus nivolumab, surgical resection, then adjuvant nivolumab further improved outcomes including EFS.

引用

页码：852 / 855

页数：4

共 50 条

[31] SBRT for early-stage NSCLC: The predominant failure pattern is distant
Bradley, J. D.
El Naqa, I.
Trovo, M.
Parikh, P.
Drzymala, R. E.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (01): : S37 - S38
[32] Racial Disparities in Early-Stage NSCLC Treatment: A Call for Action
Pellini, Bruna
Chaudhuri, Aadel A.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2024, 33 (06) : 769 - 770
[33] Neoadjuvant Chemotherapy Is Associated with Immunogenic Cell Death and Increased T Cell Infiltration in Early-Stage NSCLC
Gaudreau, P.
Negrao, M.
Mitchell, K.
Corsini, E.
Karpinets, T.
Wang, Q.
Diao, L.
Wang, J.
Federico, L.
Parra, E.
Li, J.
Behrens, C.
Correa, A.
Gomez, D.
Vaporciyan, A.
Weissferdt, A.
Tran, H.
Roarty, E.
Wistuba, I.
Reuben, A.
Haymaker, C.
Bernatchez, C.
Cascone, T.
Heymach, J.
Sepesi, B.
Zhang, J.
Gibbons, D.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S715 - S715
[34] Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): safety, efficacy, and exploratory biomarker analysis
Wood, Cameron
Lyniv, Liliana
Isaacs, James M.
Kaufman, Jacob M.
Oduah, Eziafa, I
Clarke, Jeff
Crawford, Jeffrey
Stinchcombe, Thomas
Tong, Betty C.
Wang, Xiaofei
Gu, Lin
Wigle, Dennis
Dragnev, Konstantin H.
Antonia, Scott J.
Weinhold, Kent
Ready, Neal
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2025, 13 (02)
[35] Chemotherapy and Immunotherapy in Early-Stage NSCLC: Neoadjuvant vs Adjuvant Therapy
Wakelee, Heather
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (12) : 648 - 651
[36] EXPRESSION OF ANGIOGENIC AND LYMPHANGIOGENIC GENES AS BIOMARKERS OF PROGNOSIS IN EARLY-STAGE NSCLC
Sanmartin, Elena
Jantus Lewintre, Eloisa
Sirera, Rafael
Gallach, Sandra
Uso, Marta
Blasco, Ana
Hernando, Cristina
Palomares, Eugenio
Guijarro, Ricardo
Camps, Carlos
JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1022 - S1023
[37] Pleural Contact in Clinical Early-Stage NSCLC: Recurrence Patterns and Survival
Feinstein, S.
Usera, B. M.
Ahmed, A.
Aldin, M. A. Kamal
Daly, M. E.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E372 - E373
[38] Stereotactic lung radiotherapy for early-stage NSCLC: An institution's experience
Ferreira, N.
Travancinha, C.
Antunes, T.
Fonseca, J.
Labareda, M.
Santos, F.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S56 - S56
[39] Prognostic value of "angiogenic" risk score in early-stage NSCLC.
Sanmartin, Elena
Jantus-Lewintre, Eloisa
Sirera, Rafael
Javier Sanchez, Jose
Uso, Marta
Gallach, Sandra
Blasco, Ana
Hernando, Cristina
Martinez, Nieves
Figueroa, Santiago
Diego Rolfo, Christian
Guijarro, Ricardo
Martorell, Miguel
Camps, Carlos
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[40] Immune characteristics associated with lymph node metastasis in early-stage NSCLC
Ziyu Zhang
Li Li
Yang Gao
Xiaoxiong Xiao
Liyan Ji
Zhipeng Zhou
Juan Jiang
Shiqing Liu
Jian An
Pengbo Deng
NanNan Du
Pansong Li
Xuefeng Xia
Chengping Hu
Min Li
Cellular Oncology, 2024, 47 : 447 - 461

← 1 2 3 4 5 →